Paul Brady

Paul Brady

Partner

paul.brady@abelimray.com
+44(0) 2072 429984

Professional Qualifications:
European Patent Attorney
Chartered Patent Attorney

As a Chartered and European Patent Attorney and European Patent Litigator, Paul is able to represent clients in matters before the UK Intellectual Property Office (UKIPO), the European Patent Office (EPO) and the Unified Patent Court (UPC).

Academic Qualifications:
M.A. Natural Sciences, University of Cambridge
Ph.D. Chemistry, University of Cambridge
M.Sc. Applied Biology, University of Hertfordshire

Paul joined Abel + Imray in 1997 and is based in the London office. His patent work covers the biotechnology field, as well as the chemical field, especially pharmaceuticals. He handles work for clients ranging from large international corporations to SMEs, as well as a number of universities and research institutions. In particular, Paul and his team regularly help medium-sized drug development companies as they take their pharmaceutical candidates through the pre-clinical and clinical development process, making sure that the IP assets are aligned with the drug asset.

Paul is experienced in patent prosecution work in the EPO, the UK Patent Office and worldwide. He also carries out opinion work and due diligence for licensing and take-over transactions. Paul has extensive experience in handling applications for Supplementary Protection Certificates, and he has lectured on that subject. Paul has authored the patents chapter in the UK’s Royal Society of Chemistry’s ‘Handbook of Medicinal Chemistry’ in both of its editions. Paul has also been recognised as one of the IP Stars by Managing IP every year since 2018.

Earlier in his career, Paul worked on secondment in the in-house department of a major UK-based pharmaceutical company, and he continued to work extensively for the company after his return to Abel + Imray. Having spent seven years in Switzerland in his youth, he speaks German fluently and he has a Diploma in Modern Languages from the University of Cambridge.